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Abstract
Background: The ability to efficiently and selectively target gene delivery vectors to specific cell types in vitro and
in vivo remains one of the formidable challenges in gene therapy. We pursued two different strategies to target
lentiviral vector delivery to specific cell types. In one of the strategies, vector particles bearing a membrane-bound
stem cell factor sequence plus a separate fusion protein based either on Sindbis virus strain TR339 glycoproteins
or the vesicular stomatitis virus G glycoprotein were used to selectively transduce cells expressing the
corresponding stem cell factor receptor (c-kit). An alternative approach involved soluble avian sarcoma/leukosis
virus receptors fused to cell-specific ligands including stem cell factor and erythropoietin for targeting lentiviral
vectors pseudotyped with avian sarcoma/leukosis virus envelope proteins to cells that express the corresponding
receptors.
Results: The titers of unconcentrated vector particles bearing Sindbis virus strain TR339 or vesicular stomatitis virus
G fusion proteins plus stem cell factor in the context of c-kit expressing cells were up to 3.2 × 10
5 transducing
units per ml while vector particles lacking the stem cell factor ligand displayed titers that were approximately 80
fold lower. On cells that lacked the c-kit receptor, the titers of stem cell factor-containing vectors were
approximately 40 times lower compared to c-kit-expressing cells.
Lentiviral vectors pseudotyped with avian sarcoma/leukosis virus subgroup A or B envelope proteins and bearing
bi-functional bridge proteins encoding erythropoietin or stem cell factor fused to the soluble extracellular domains
of the avian sarcoma/leukosis virus subgroup A or B receptors resulted in efficient transduction of erythropoietin
receptor or c-kit-expressing cells. Transduction of erythropoietin receptor-expressing cells mediated by bi-functional
bridge proteins was found to be dependent on the dose, the correct subgroup-specific virus receptor and the cor-
rect envelope protein. Furthermore, transduction was completely abolished in the presence of anti-erythropoietin
antibody.
Conclusions: Our results indicate that the avian sarcoma/leukosis virus bridge strategy provides a reliable approach
for cell-specific lentiviral vector targeting. The background levels were lower compared to alternative strategies
involving Sindbis virus strain TR339 or vesicular stomatitis virus fusion proteins.
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Targeted vector delivery has been approached in a num-
ber of ways [1]. For example, the host range of retroviral
vectors including that of lentiviral vectors can be
expanded or altered by a process known as pseudotyp-
ing. Pseudotyped retroviral vectors consist of vector par-
ticles bearing envelope (Env) glycoproteins derived from
other enveloped viruses. Such particles possess the trop-
ism of the virus from which the glycoprotein was origin-
ally derived [2].
It has been challenging to develop lentiviral vectors
that display a reduced tropism for the natural receptor
and an increased specificity for a chosen receptor to
allow targeted transduction of specific cell types in vitro
and in vivo [3]. Such targeting approaches have involved
engineered versions of the Sindbis virus E2 glycoprotein
bearing either a Staphylococcus aureus protein A
domain [4-14] or single chain antibody fragments fused
in-frame to the E2 glycoprotein coding region [15],
allowing antibody-mediated cell targeting in the pre-
sence of the Sindbis virus E1 fusion protein. A related
strategy that uncouples the target cell recognition func-
tion from the fusion function presents them as separate
proteins on the vector’s surface. This has proven more
flexible and has facilitated cell-specific targeting of gam-
maretroviral [16] and lentiviral vectors [17-22]. One
drawback of these approaches is that background trans-
duction levels are substantial even in the absence of the
ligand or when using cells lacking the corresponding
receptors due to the leakiness of the mutations that
were introduced into the Sindbis virus E2 glycoprotein
for abolishing cell binding.
Alternative approaches for cell-specific targeting of
alpharetroviral and gammaretroviral vectors have been
described. These involve the use of ligand proteins or
cell-specific antibodies as a bridge to target vectors car-
rying unmodified avian sarcoma/leukosis virus (ALV)
Env proteins to specific cells in vitro [23-27]. This sys-
tem is attractive because of its flexibility to accommo-
date cell-specific ligands without impacting the Env
glycoprotein. Also, the reported background transduc-
tion levels were low.
Here we show that HIV-1-based lentiviral vectors are
able to form efficient pseudotypes with Env glycopro-
teins derived from ALV subgroups A and B. Further-
more, vectors pre-incubated with bi-functional bridge
proteins encoding human erythropoietin (Epo) or stem
cell factor (SCF) fused to the soluble extra-cellular
domains of the ALV subgroup A and B receptors
resulted in efficient transduction of mammalian cells
expressing the human erythropoietin receptor (EpoR) or
c-kit. We also show that targeted cell transduction can
be achieved using lentiviral vectors particles bearing a
membrane-bound form of SCF in conjunction with an
independent fusion domain derived from VSV-G [28,29]
or the glycoproteins derived from a non-heparan sul-
fate-binding strain of Sindbis virus [30].
Results
Targeting of c-kit-expressing cells with lentiviral vectors
bearing Sindbis virus strain TR339 glycoproteins and
human SCF
We first tested a cell-targeting approach using an EGFP-
expressing lentiviral vector (LV-EGFP) pseudotyped with
modified glycoproteins derived from the Sindbis virus
TR339 strain [30] and bearing a membrane-bound ver-
sion of SCF. Such membrane-bound forms of SCF have
been shown before to be biologically active and to facili-
tate targeted retroviral transduction [16,31]. Unlike cell
culture-adapted strains of Sindbis virus that exhibit effi-
cient initial attachment to cell surface heparan sulfate
receptors, the TR339 strain exhibited little to no interac-
tion with heparan sulfate and low binding to cell sur-
faces while it was still able to chaperone the E1 fusion
protein [32]. Based on these findings, we surmised that
the Sindbis virus strain TR339 E2 and the E1 glycopro-
teins would promote vector uptake by target cells con-
taining a specific receptor (such as c-kit) provided that
an appropriate ligand is also present on the vector parti-
cle. An outline of the TR339 proteins used in this work
is presented in Fig. 1A. A Western blot analysis of vec-
tor particles that had been concentrated by ultracentri-
fugation was carried out to test whether SCF was stably
associated with such particles. Consistent with earlier
results [16,31], SCF was found to be present in concen-
trated lentiviral vector preparations (data not shown).
Such vector particles were then tested functionally. Fig.
1B shows that lentiviral vector particles pseudotyped
with strain TR339-derived glycoproteins (SB-Env) and
bearing SCF resulted in efficient transduction of 293-c-
kit cells (Fig. 1B, top panels and Fig. 1C and 1D) while
vector particles lacking SCF displayed lower transduc-
tion efficiencies (Fig. 1B top panels). The titers of
unconcentrated SB-Env pseudotypes bearing SCF on c-
kit-expressing 293 cells were approximately 80 fold
higher than those observed with vectors lacking SCF
(3.2 ± 0.04 × 10
5 transducing units, TU/ml vs. 4.1 ± 2.0
×1 0
3 TU/ml). The titers on 293T cells that do not
express c-kit were 2.0 ± 1.4 × 10
3 TU/ml for vector par-
ticles lacking SCF and 1.1 ± 0.1 × 10
4 TU/ml for parti-
cles containing SCF (Fig. 1B, bottom panels and Fig. 1C
and 1D). This result indicates that a majority of the
transduction events were mediated by SCF-c-kit interac-
tions. Fig. 1D shows that vector particles bearing SB-
Env plus SCF retained the ability to transduce 293-c-kit
cells after concentration by ultracentrifugation. The
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4 TU/ml
before concentration and 6.5 ± 2.1 × 10
6 TU/ml after a
300 fold concentration.
On MO7-e cells, a cell line expressing c-kit [31,33]
lentiviral vectors pseudotyped with SB-Env and bearing
SCF revealed titers around 1.2 ± 0.4 × 10
4 TU/ml while
vectors lacking SCF revealed titers < 10
2 TU/ml (data
not shown). These results confirm the results obtained
with the 293-c-kit cells.
Cell specific targeting using lentiviral particles displaying
human SCF and a fusion domain derived from VSV-G
We next investigated an alternative lentiviral vector tar-
geting strategy in which a membrane-bound form of
SCF was incorporated into EGFP-encoding lentiviral
(LV-EGFP) particles containing a truncated version of
the VSV-G glycoprotein (VSV-GS). VSV-GS consists of
a truncated ectodomain bearing a membrane-proximal
stem region and the native trans-membrane and cyto-
plasmic domains (Fig. 2A). The VSV-GS protein was
previously shown to enhance the cell-cell fusion activity
of heterologous Env proteins [28,29]. LV-EGFP particles
bearing VSV-GS resulted in specific transduction of 293
cells expressing c-kit as judged by FACS (Fig. 2B). It
was interesting to note that vector particles bearing SCF
but no fusion domain resulted in low but detectable
transduction of 293-c-kit cells. Low but reproducible
transduction of 293-c-kit cells with vectors containing
SCF but lacking VSV-GS was also observed with b-
galactosidase-encoding vectors as judged by X-Gal stain-
ing of transduced cells (data not shown).
As shown in Fig. 2C, LV-EGFP particles decorated
with SCF and containing VSV-GS resulted in the
appearance of EGFP-positive MO7-e cells (upper right
panel) while LV-EGFP particles lacking SCF did not
(upper middle panel). Furthermore, transduction was
abolished following addition of a polyclonal goat anti-
SCF antibody (Fig. 2C, lower center and lower right
panels) but not after the addition of normal goat serum.
The vector titers using MO7-e cells expressing c-kit
were 6.2 ± 1.5 × 10
4 TU/ml. Following a 250-fold con-
centration by ultracentrifugation, the titers reached 6.9
±3 . 8×1 0
6 TU/ml (data not shown). This shows that
the ability of VSV-GS-containing vector particles to
transduce cells was only minimally affected by
ultracentrifugation.
Transduction of human cells expressing a chimeric ALV
receptor using lentiviral vectors pseudotyped with the
ALV-A or ALV-B Env glycoproteins
We next wished to determine the potential of a bridge
targeting strategy for cell-specific lentivirus vector tar-
geting involving cell-specific ligands linked in-frame to
the soluble extracellular domains of ALV receptors
referred to as TVA and TVB, respectively. Such bridge
strategies were used before to target alpharetroviral and
gamaretroviral vectors carrying ALV Env proteins to
mammalian cells bearing specific receptors [23-27]. To
evaluate this approach, lentiviral vector pseudotypes pre-
pared using glycoproteins derived from ALV subgroups
A or B (referred to as ALV-A Env and ALV-B Env,
respectively) were first tested on 293 cells expressing the
corresponding TVA and TVB receptors. For transduc-
tion, vector particle numbers were adjusted based on
p24 antigen levels. As shown in Fig. 3 (lower panels)
and Table 1, 293-DK7 cells expressing a chimeric TVA-
TVB receptor [34] were transduced with relatively high
efficiency reaching titers between 10
5 to 10
6 TU/ml
(Table 1) while such pseudotypes did not transduce 293
cells lacking the corresponding receptors. Following a
250-fold concentration by ultracentrifugation, titers
between 10
7 to 10
8 TU/ml were obtained (Table 1).
This indicated that such pseudotypes survived concen-
tration by ultracentrifugation.
Expression of recombinant TVA and TVB bridge proteins
In a next step, bi-functional fusion proteins consisting of
a 107 amino acid-long soluble extracelluar domain of
the TVA receptor or a 155 amino acid-long soluble
extracellular domain of the TVB receptor fused in-frame
to the mature form of human Epo and containing a V5
tag sequence were generated (Fig. 4A). A 9-amino acid
proline-rich linker sequence [23] derived from the hinge
region of the rabbit Fc chain was placed in between the
TVA or TVB domains and the Epo sequence (Fig. 4A).
The amounts of the fusion proteins released into the
cell culture supernatant from stably transfected 293T
cell clones were analyzed by an ELISA test using an
antibody directed against the V5 epitope present in the
fusion proteins. The results from the ELISA assay indi-
cated that the concentrations of the unmodified soluble
TVA domain and that of the TVA-Epo fusion protein
were in the range of 300 - 800 V5 units/ml while the
TVB and TVB-Epo protein levels were in the range of
1,500 - 2,000 V5 units/ml (data not shown).
A Western blot analysis of cell culture supernatants
using anti-V5 antibody showed that the sizes of the TVA
protein ranged from 28 to 35 kDa, while the sizes of the
TVA-Epo protein ranged from 55 to 60-kDa (Fig. 4B).
These findings are consistent with the view that posttran-
slational modifications affected the migration of the TVA
proteins in SDS polyacrylamide gels [23]. The TVB protein
displayed an apparent molecular weight around 28 kDa
which is slightly larger than the expected size. The TVB-
Epo protein showed a molecular weight around 55 kDa.
Cell-specific transduction by lentiviral vectors
pseudotyped with ALV-A or ALV-B Env glycoproteins
mediated by Epo-EpoR interactions
To test the capacity of TVA-Epo and TVB-Epo fusion
proteins to act as a bridge to target lentiviral vectors
pseudotyped with the ALV-A and ALV-B Env proteins
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Page 3 of 15Figure 1 Transduction of c-kit-expressing 293 cells using lentiviral vectors pseudotyped with the Sindbis virus strain TR339
glycoproteins and bearing SCF. (A) Schematic representation of the modified Sindbis virus strain TR339 proteins. The sequence of the
modified E3 protein is shown. It encodes 66 amino acids including the signal peptide for the E2 protein. E2 consists of 423 amino acids, and the
6K and E1 proteins encode 55 and 439 amino acids, respectively. The numbers refer to the ends of the respective protein domains. (B)
Representative FACS profiles. Top panels: 293-c-kit cells transduced with vectors prepared using 0 and 6 μg of the SCF-encoding pUB-HuMGF
plasmid; Top left panel: Untransduced cells. Bottom panels: 293T cells transduced with vectors prepared using 0 and 6 μg of the SCF-encoding
pUB-HuMGF plasmid; Bottom left panel: Untransduced cells. The percentages of EGFP-positive cells are indicated. (C) Unconcentrated vector
titers on 293 cells expressing c-kit (striped bars) and on 293T cells (open bars) three days after transduction. The titers shown represent the
mean ± standard deviation (SD) obtained from three independent experiments. (D) Determination of concentrated vector titers. Vectors were
concentrated 300 fold by ultracentrifugation. The titers shown represent the mean ± SD from three to six independent experiments. Striped
bars: 293 cells expressing c-kit; Open bars: 293T cells.
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Page 4 of 15Figure 2 Transduction of c-kit-expressing cells using lentiviral vectors bearing a VSV-G-derived fusion domain and SCF. (A) Schematic
representation of the VSV-GS fusion protein. HA: An HA epitope sequence (KYPYDVPDYA) was included to facilitate detection of the VSV-GS
protein. The truncated ectodomain, the transmembrane domain (TM) and the cytoplasmic tail (CT) are indicated. The numbers refer to the ends
of the respective protein domains. (B) Transduction of 293T and 293-c-kit cells using LV-EGFP vector particles bearing the VSV-GS fusion domain
and/or SCF. Additional controls included LV-EGFP vector particles bearing VSV-GS but lacking SCF and vector particles lacking both VSV-GS and
SCF. Left panels: 293T cells; Right panels: 293-c-kit cells. Cells were analyzed by FACS three days later. FACS profiles of representative assays are
shown. (C) Transduction of MO7-e cells using EGFP-encoding lentiviral vector particles displaying SCF plus the VSV-GS fusion domain. Cells were
transduced by spinoculation. Vector titers were determined by FACS analysis three days later. Goat anti-hSCF was added during transduction of
the samples shown in the lower center and lower right panels. Normal goat serum referred to as control serum was added to the sample
shown in the bottom left panel.
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duced with LV-EGFP particles that had been preloaded
with the TVA-Epo or TVB-Epo fusion proteins. As
shown in Fig. 5A (bottom left and middle panels), LV-
EGFP vectors pseudotyped with the ALV-A Env glyco-
protein after pre-incubation with the TVA-Epo fusion
protein transduced 293T-EpoR cells efficiently while
vectors that had been pre-incubated using unmodified
TVA (top middle and right panels) or TVB-Epo (bottom
right panel) did not.
Similar assays were performed with ALV-B pseudo-
types pretreated with TVB and TVA fusion proteins or
unmodified TVB or TVA. As indicated in Fig. 5B, 293T-
EpoR cells were transduced efficiently using vectors pre-
incubated with TVB-Epo proteins (Fig. 5B, second row),
but not with vectors pre-incubated with unmodified
TVB or TVA proteins (Fig. 5B, rows one and three).
Interestingly, however, unlike the ALV-A pseudotypes
which did not transduce 293T-EpoR cells efficiently
after pre-incubation with TVB-Epo proteins, low levels
of transduction were observed when the cells were
transduced using ALV-B-pseudotyped vectors bearing
TVA-Epo proteins (Fig. 5B, row four), possibly indicat-
ing a weak interaction between the ALV-B Env glyco-
protein and TVA-Epo. Transduction of 293T cells using
ALV-B pseudotypes containing TVB-Epo was below the
level of detection (data not shown).
The titers of ALV-A and ALV-B pseudotypes pre-
loaded with TVA-Epo or TVB-Epo bridge proteins pro-
duced under optimized conditions after a 250-fold
concentration by ultracentrifugation were 8.60 ± 0.70 ×
10
7 TU/ml and 9.2 ± 2.6 × 10
7 TU/ml, respectively
(Table 1). These titers compare favorably with those
obtained using 293 DK-7 cells expressing the chimeric
TVA-TVB receptor which were 1.57 ± 0.47 × 10
8 TU/
ml for pseudotypes bearing the ALV-A Env and 1.20 ±
0.30 × 10
7 TU/ml for pseudotypes bearing the ALV-B
Figure 3 Transduction of 293 cells expressing a chimeric TVA/TVB receptor using lentiviral vectors pseudotyped with the ALV-A and
ALV-B Env glycoproteins. Upper panel: 293 cells transduced with LV-EGFP vectors pseudotyped using ALV-A Env, or ALV-B Env. Lower panel:
293 DK-7 cells transduced using LV-EGFP pseudotyped with ALV-A Env or ALV-B Env. 1.64 × 10
3 pg of p24 were used for ALV-A Env
pseudotypes, and 0.7 × 10
3 pg of p24 for ALV-B pseudotypes. Control refers to mock-transduced cells. FACS profiles of representative assays are
shown.
Table 1 Comparison of titers of lentiviral vectors
pseudotyped with ALV-A or ALV-B Env glycoproteins in
cell lines expressing TVA and TVB receptors, EpoR or c-
kit
Vector pseudotypes Cells Titers (TU/ml)
d
ALV-A 293 DK-7
a 1.57 ± 0.47 × 10
8
ALV-A/Epo 293 or 293T
293T-EpoR
b
<10
4
8.60 ± 0.70 × 10
7
ALV-A/SCF MO7-e
c 1.17± 0.25 × 10
7
ALV-B 293 DK-7
a 1.20 ± 0.30 × 10
7
ALV-B/Epo 293 or 293T
293T-EpoR
b
<10
4
9.2 ± 2.6 × 10
7
ALV-B/SCF MO7-e
c 8.38 ± 3.60 × 10
6
aTransduction efficiencies of ALV-A and ALV-B pseudotypes were determined
on 293 DK-7 cells, a clonal cell line expressing the chimeric TVA/TVB receptor.
Vectors used were concentrated 250-fold. The titers of un-concentrated virus
were 8.12 ± 4.4 × 10
5 (ALV-A) and 2.0 ± 0.9 × 10
5(ALV-B) respectively.
bPseudotypes preloaded with TVA-Epo or TVB-Epo were used to transduce a
293T-based clonal cell line expressing EpoR. Vectors used were concentrated
250-fold. The titers of un-concentrated virus were 7.27 ± 0.77 × 10
5 (ALV-A)
and 7.80 ± 0.46 × 10
5 (ALV-B) respectively.
cPseudotypes preloaded with TVA-SCF or TVB-SCF were used to transduce c-
kit-expressing MO7-e cells. Vectors used were concentrated 250-fold.
dTiters presented represent the mean ± SD from three independent
experiments using concentrated vector stocks.
Zhang et al. Retrovirology 2010, 7:3
http://www.retrovirology.com/content/7/1/3
Page 6 of 15Env (Table 1), indicating that bridge-mediated transduc-
tion was very efficient.
To demonstrate that Epo/EpoR-mediated transduction
was specific, a monoclonal anti-Epo antibody was
included during the preloading step of the vector pseu-
dotypes with the bridge proteins. As shown in Fig. 5C,
the transduction of EpoR-expressing cells was inhibited
in a dose-dependent manner when increasing amounts
of the anti-Epo antibody were included, while a control
monoclonal antibody (anti-Flag) had no effect.
Incorporation of bridge proteins during lentiviral vector
production
Boerger et al. have shown that Moloney murine leuke-
mia virus-based vectors pseudotyped with the ALV-B
Env protein and decorated with TVB fusion proteins
could be produced directly from vector packaging cells
[24]. This is an attractive feature in that the in vitro pre-
loading step can be bypassed. To test whether lentiviral
vectors bearing ALV-A or ALV-B Env glycoproteins
could be preloaded with TVA-Epo or TVB-Epo fusion
proteins during vector production, vectors were pre-
pared by co-transfecting 293T cells with four different
plasmids including an EGFP-expressing lentiviral vector
plasmid, a packaging plasmid, an ALV-A or ALV-B Env
plasmid, and the pTVA-Epo or pTVB-Epo plasmids. As
shown in Fig. 6, vector titers were critically depended
on the amounts of the pTVA-Epo or pTVB-Epo plas-
mids added during vector production. The highest titers
Figure 4 Analysis of TVA and TVB bridge proteins. (A) Schematic representation of TVA and TVB fusion proteins. The ends of the
unprocessed TVA and TVB extracellular domains including their signal peptide sequences are shown. To generate TVA-Epo and TVB-Epo, the
human Epo sequence encoding amino acids 28 to 193 of the mature protein was placed downstream of the linker-encoding sequence. The
numbers refer to the ends of the respective protein domains. (B) Western blot analysis of TVA and TVB fusion proteins. Cell supernatants
collected from 293T cells stably expressing TVA and TVB proteins were analyzed by Western blotting using monoclonal anti-V5 antibody. Lanes
1, 2, 4, and 5: Supernatants from cells producing TVA, TVB, TVB-Epo and TVA-Epo proteins, respectively. Lane 3: Control 293T cells. The amounts
loaded were equalized based on the V5 epitope-specific ELISA assay described in Materials and Methods.
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Page 7 of 15Figure 5 Transduction of 293T-EpoR cells using ALV-A or ALV-B-pseudotyped lentiviral vectors preloaded with TVA-Epo or TVB-Epo
bridge protein. (A) Specificity of TVA-Epo-mediated transduction. 293T-EpoR cells were transduced with ALV-A-pseudotyped LV-EGFP vectors
preloaded with TVA-Epo or TVB-Epo bridge proteins and subjected to FACS analysis three days later. Aliquots of a concentrated vector stock
corresponding to 5 × 10
4 TU (determined on 293 DK-7 cells) were preincubated with cell culture supernatants containing TVA (upper center
panel and upper right panel), TVA-Epo (lower left panel and lower center panel) or TVB-Epo (lower right panel). The amounts of bridge proteins
added (expressed as V5 units) are indicated in parentheses. (B) Specificity of TVB-Epo-mediated transduction. 293T-EpoR cells were transduced
with ALV-B-pseudotyped vectors preloaded with TVB-Epo and TVA-Epo bridge proteins and subjected to FACS analysis 3 days later. Aliquots of a
concentrated vector stock corresponding to 1.2 × 10
4 TU (determined on 293 DK-7 cells) were preincubated with cell supernatants containing
TVB or TVB-Epo (top two panels), or TVA or TVA-Epo (bottom two rows). The amounts of TVB and TVB-Epo proteins added (expressed as V5
units) are indicated. Representative FACS profiles are shown. (C) Inhibition of TVA-Epo and TVB-Epo-mediated transduction of 293T-EpoR cells by
anti-Epo antibody. 293T-EpoR cells were transduced using an EGFP-encoding lentiviral vector pseudotyped with the ALV-A Env (left panel) or the
ALV-B Env (right panel). Vectors were exposed to cell supernatants containing TVA-Epo in the presence of monoclonal anti-Epo antibody or
monoclonal anti-Flag antibody (as a control) on ice for 30 min. Transduced cells were subjected to FACS analysis three days later. The
percentages of EGFP-positive cells are indicated. Representative data from two independent assays are shown.
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Page 8 of 15reached for TVA-Epo-containing particles were 5.3 ±
0.3 × 10
5 TU/ml (Fig. 6A, open bars). Subjecting these
in vivo-preloaded vectors to a subsequent preloading
step in vitro using the TVA-Epo protein had an additive
effect on the titers depending on the amount of the
TVA-Epo plasmid added during the transfection step
(Fig. 6A, striped panels). The highest titers obtained in
this way were 1.2 ± 0.4 × 10
6 TU/ml.
Similar experiments were conducted by including
pTVB-Epo during preparation of ALV-B pseudotypes
(Fig. 6B). The highest titers obtained were 4.4 ± 0.9 ×
10
4 T U / m l( F i g .6 B ,o p e nb a r s ) .H o w e v e r ,t h et i t e r s
increased substantially following exposure of such pseu-
dotypes to the TVB-Epo protein in vitro reaching titers
around 2.0 ± 0.8 × 10
6 TU/ml (Fig. 6B, striped bars). It
is also evident from Fig. 6A and 6B that the relative
amounts of the bridge proteins present during vector
loading post-production or during production critically
affect vector titers.
In order to confirm that bridge proteins were specifi-
cally bound to vector particles, ALV-A pseudotypes
were concentrated by ultracentrifugation. Western blot
analyses using anti-V5 antibody revealed the presence of
TVA-Epo on vector particles after concentration.
Furthermore, the relative levels of the bridge proteins
detected in concentrated vector particles correlated well
with the amounts of pTVA-Epo used during vector pro-
duction (Fig. 6C).
Cell-specific transduction by lentiviral vectors
pseudotyped with ALV-A or ALV-B glycoproteins
mediated by SCF-c-kit interactions
In order to test if bridge protein-mediated transduction
by lentiviral vectors can be applied to other ligands and
cell lines, bi-functional proteins containing the soluble
extracellular domain of TVA or TVB fused to the solu-
ble portion of human SCF were generated and tested in
MO7-e cells that express c-kit. As shown in Table 1, the
titers of concentrated ALV-A (ALV-B) pseudotypes pre-
loaded with TVA-SCF (or TVB-SCF) in MO7-e cells
ranged from 10
6 to 10
7 TU/ml.
Discussion
Various strategies have been explored to target lentiviral
vector delivery to specific cells in vitro and in vivo
including approaches involving engineered versions of
the Sindbis virus E2 glycoprotein bearing either a Sta-
phylococcus aureus protein A domain [4-13], or single
chain antibody fragments [15]. In a related targeting
strategy, the cell recognitionf u n c t i o na n dt h ef u s i o n
function mediated by the Sindbis virus E2 glycoprotein
are carried out by separate proteins that are anchored in
the vector’s membrane [17-19]. A drawback with these
approaches is that they involve glycoproteins derived
from laboratory-adapted strains of Sindbis virus
Figure 6 Transduction of 293T-EpoR cells using lentiviral
vector pseudotypes preloaded with TVA-Epo or TVB-Epo
during vector production. (A) Open bars: ALV-A Env-pseudotyped
lentiviral vectors prepared in 6-well plates using different amounts
of the pTVA-Epo plasmid ranging from 0 to 1.0 μg. Striped bars: In
vivo-preloaded vectors were subjected to a subsequent preloading
step in vitro using the TVA-Epo protein (40 V5 units of TVA-Epo per
50 μl of virus stock). (B) Open bars: ALV-B Env-pseudotyped lentiviral
vectors prepared in 6-well plates using different amounts of pTVB-
Epo ranging from 0 to 3.5 μg. Striped bars: In vivo-preloaded vectors
were subjected to a subsequent preloading step in vitro using the
TVB-Epo protein (14 V5 units of TVB-Epo per 50 μl of virus stock).
The titers shown in panels A and B represent the mean ± SD from
three independent experiments. (C) Western blot analysis of ALV-A-
pseudotyped lentiviral vectors prepared by co-transfection with
different amounts of pTVA-Epo. Lanes 1-5: Two-μl aliquots of vector
stocks prepared by co-transfection using 0.5 μg (lane 1), 0.1 μg (lane
2), 0.04 μg (lane 3), 0.02 μg (lane 4) and 0 μg (lane 5) of the pTVA-
Epo plasmid DNA and concentrated ~35-fold by ultracentrifugation
were analyzed. Lane 6: Unconcentrated vectors prepared using 0.4
μg of the pTVA-Epo plasmid DNA. The molecular weights of the
protein markers used are indicated.
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Page 9 of 15necessitating the introduction of mutations to abrogate
high efficiency binding to cell surface receptors such as
heparan sulfate. Unfortunately, background transduction
levels in the absence of the ligand or with cells lacking
the corresponding receptors were substantial due to the
leakiness of the mutations that were introduced to abol-
ish cell binding [6].
Alternative approaches for lentiviral vector targeting
are emerging. For example, in a recent report Funke et
al. [35] have shown that the measles virus hemagglutinin
(H) and fusion protein (F) are capable of pseudotyping
of HIV-1 vectors. Moreover, engineered H proteins dis-
playing cell-specific ligands or single chain antibodies
resulted in specific transduction of target cells. While
the background transduction levels in the absence of the
ligand were low, the concentration of such pseudotypes
by centrifugation has been challenging.
In this study, we investigated the efficiency and selec-
tivity of a cell targeting approach involving lentiviral
vectors pseudotyped with the Sindbis virus strain TR339
glycoproteins [30] plus a separate cell binding domain.
The Sindbis virus TR339 strain was originally derived
from the AR339 strain which represents the prototype
alphavirus and whose sequence differs markedly from
that of the common Sindbis virus laboratory strains that
have emerged after selection for efficient growth in cell
culture [36]. Such laboratory strains bear mutations that
facilitiate binding of the virus to heparan sulfate [30], a
property that is clearly not desirable in the context of
targeting stategies. Our data indicate that the titers of
SCF-containing vectors bearing the Sindbis virus TR339
glycoproteins were up to 3.2 ± 0.04 × 10
5 TU/ml on c-
kit-expressing 293 cells, while the titers of lentivirus par-
ticles lacking SCF were some 80 fold lower (Fig. 1C).
These background transduction levels are comparable to
those reported previously by Morizono et al. [6] using
multiply mutated versions of a Sindbis virus laboratory
strain-derived E2 protein. However, it is likely that the
unmodified E2 protein of the TR339 strain retains con-
siderably more of the non-attachment activity of this
protein than the highly modified version used by Mori-
zono et al. Therefore, it is possible that use of the wild
type E2 may improve the efficiency of pseudotype parti-
cle production. However, a direct comparison of infec-
tivity per particle of the different vectors will be
required to answer this question.
We also explored a targeting approach involving vec-
tor particles containing a membrane-proximal fusion
domain (VSV-GS) derived from the VSV G glycoprotein
[29] plus a separate cell binding domain. The results
reported earlier by Jeetendra et al. [29] showed that the
membrane-proximal 42 amino acids (residues 421 to
461) of the VSV-G protein ectodomain together with
the TM region and the cytoplasmic tail were able to
potentiate the membrane fusion activity of heterologous
viral fusion proteins when the two proteins were co-
expressed. We investigated the efficiency of the VSV-GS
domain to target SCF-displaying lentiviral vector parti-
cles to c-kit expressing cells. The results presented in
Figs. 2B and 2C show that specific transduction of c-kit-
expressing 293 and MO7-e cells was achieved and that
transduction efficiencies using SCF-bearing vectors were
40 fold higher (1.4 ± 0.2 × 10
4)c o m p a r e dt ov e c t o r s
lacking SCF (3.5 ± 1.5 × 10
2). Overall, the titers
obtained with VSV-GS-containing particles were low,
possibly because VSV-GS mostly promoted hemifusion
events [29]. It was evident that MO7-e cells were trans-
duced less efficiently than 293-c-kit cells although c-kit
levels were higher in MO7-e cells as judged by FACS
(data not shown). This may be due to the fact that the
transduction conditions used for MO7-e cells were not
optimal. This view is enforced by the observation that
VSV-G pseudotypes on MO7-e cells did relatively poorly
compared to 293-c-kit cells (data not shown).
It was interesting to note that lentiviral vectors bear-
ing SCF, but lacking the VSV-GS fusion domain, were
capable of transducing 293-c-kit cells but not 293T cells
(Fig. 2B). This may indicate that SCF provided some
cryptic fusion function. Furthermore, the transduction
experiments involving 293T cells presented in Fig. 1D
revealed that transduction efficiencies of vector particles
containing SCF increased in a dose-dependent manner.
This may have resulted from the binding of vector parti-
cles to 293T cells through nonspecific SB-Env interac-
tions and augmented fusion triggered by SCF.
Young and collaborators have shown that alpharetro-
viral and gammaretroviral vectors carrying unmodified
ALV envelope glycoproteins and bearing specific ligand
proteins or single chain antibody as a bridge were cap-
able of targeting specific cells in vitro [23-27]. An attrac-
tive feature of this bridge targeting system is that the
background transduction levels were low. These findings
promoted us to investigate the capacity of lentiviral vec-
tors bearing the ALV-A and ALV-B Env glycoproteins
to target specific cells in vitro using soluble TVA and
TVB bridge proteins bearing cell-specific ligands. Fig. 3
shows that HIV-1-based vectors were efficiently pseudo-
typed using both the ALV-A and ALV-B Env glycopro-
teins as judged from transduction experiments involving
293-DK7 cells that express a hybrid ALV-A/B receptor
[34]. The titers obtained were 1.57 ± 0.47 × 10
8 TU/ml
for pseudotypes bearing the ALV-A Env protein after a
250-fold concentration and 1.20 ± 0.30 × 10
7 TU/ml for
ALV-B pseudotypes (Table 1). The ALV-A pseudotype
titers obtained compare favorably to those reported pre-
viously by Lewis et al. 2001 [37]. It was interesting to
note, however, that the titers reported by Lewis et al.
involving an unmodified version of the ALV-A Env
Zhang et al. Retrovirology 2010, 7:3
http://www.retrovirology.com/content/7/1/3
Page 10 of 15protein were considerably lower, less than 10
4 TU/ml,
while ALV-A glycoproteins bearing a truncated cyto-
plasmic tail or a chimeric cytoplasmic tail were some 5-
fold higher. Our work involved unmodified ALV-A Env
and ALV-B Env proteins bearing intact cytoplasmic
tails. Yet the titers were consistently well above 10
5 TU/
ml for both ALV-A and ALV-B pseudotypes (Table 1).
The reason for this discrepancy is not clear; it may be
due to differences in the TVA-expressing 293 cell lines
that were used for vector titration.
Boerger et al. [24] have previously shown that retro-
viral vectors preloaded with TVB-EGF bridge proteins
were relatively thermostable and could be generated
directly from vector-producing cells. Our findings show
that the same approach is feasible as far as TVB-Epo-
containing lentiviral vector particles are concerned (Fig.
6B). Interestingly, the same approach was applicable to
TVA-Epo-containing lentiviral vectors as well (Fig. 6A).
This was possibly facilitated by metastable fusion-
incompetent ALV-A Env/TVA-Epo complexes that were
unable to complete the fusion reaction during vector
production at neutral pH [38,39].
An attractive feature of the bridge strategy involving
ALV-A Env pseudotyped vectors is that background
levels were low (Fig. 5A). However, the same kind of
tight specificity was not seen with ALV-B-pseudotyped
lentiviral vector particles. Such particles displayed resi-
dual transduction in the presence of the heterologous
TVA-Epo bridge protein but not in the presence of
unmodified TVA alone. The reason for this difference in
the binding specificities is not clear at present.
Conclusions
In summary, the bridge approach provides a promising
strategy for cell-specific targeting of lentiviral vectors.
The most promising results were obtained using ALV-A
Env-pseudotyped vectors decorated with soluble TVA
receptors bearing cell-specific ligands. A chief advantage
of this strategy compared to other lentiviral targeting
strategies includes lower background transduction.
What remains to be determined in the future are the
relative transduction efficiencies and specificities in vivo
of the pseudotypes made with the different approaches.
Methods
Plasmids
Plasmid pcDNA-SB-Env encoding the Sindbis virus
strain TR339 E3, E2, 6K and E1 proteins (Fig. 1A)
[30,32] was generated as follows: A synthetic DNA frag-
ment (160 bp) encoding the first 45 amino acids of the
E3 protein with an ApaIs i t ea tt h e5 ’-end and a StuI
site at the 3’ end was used to replace the ApaI-StuI frag-
ment present in the Sindbis replicon glycoprotein helper
pINT [30]. From the resulting plasmid, a 3.3-kb
HindIII-XhoI DNA fragment was subcloned into
pcDNA3.1/Zeo(+) (Invitrogen, Carlsbad, CA) to gener-
ate pcDNA-SB-Env. An expression plasmid encoding a
membrane-bound form of human SCF was generated by
subcloning a HindIII-BamHI fragment derived from the
pBluescriptSK-hMGF plasmid (a gift from Paul Schwar-
zenberger, LSU Health Sciences Center, New Orleans,
LA) into the pUB6/V5-HisB expression plasmid (Invitro-
gen), resulting in pUB6-HuMGF. A synthetic DNA frag-
ment encoding the membrane-proximal stem region of
the VSV-G ectodomain (G stem), transmembrane and
cytoplasmic domains (amino acids 395 to 511) [28,29]
was subcloned into the expression vector pUB6/V5-
HisB to generate pUB6-VSV-GS. Plasmid pCB6 EnvA
encoding the ALV-A Env glycoprotein [40] was obtained
from Galen Fisher (National Cancer Institute, Bethesda,
MD). Plasmid pAB7 encoding the ALV-B Env glycopro-
tein [24] was kindly provided by John Young (University
of Wisconsin, Madison, WI). A DNA fragment encoding
the extracellular domain of TVA (amino acids 1-107)
linked in-frame to a proline rich sequence
(PPPELLGGP) was PCR-amplified using pCB6 Tva950
[41] (a gift from Galen Fisher) as a template and pri-
mers TVA-F (5’-GTTCTAGCTAGCGCTGTGCGCGG-
TACCGATATG-3’) and TVA-Linker-R (5’-
GATTCCCTCGAGCGGTCCCCCCAGGAGTT-
CAGGGGGTGG-3’). The PCR product was digested
with NheIa n dXhoIa n dc l o n e di n t op c D N A 6 / V 5 - H i s
(Invitrogen) cut with NheI and XhoI, resulting in pTVA-
V5 which encodes the TVA-PPPELLGGP protein fused
in-frame to a V5 epitope sequence. Similarly, pTVB-V5
was generated by cloning a PCR fragment encoding the
extracellular domain of TVB (amino acids 1 to 155)
fused in-frame to the PPPELLGGP sequence into
pcDNA6/V5-His. To do this, pBK7.62 (a gift from John
Young) [42] was used as a template for PCR. The pri-
mers used were TVB-F (5’-GTTCTAGCTAGCGA-
GATGCGCTCAGCTGCGCTCC-3’)a n dT V B - L i n k e r - R
(5’-GATTCCCTCGAGCGGTCCCCCCAGGAGTT-
CAGGGGGTGGAGTGGAGGAGCTGGAGGAGAT-3’).
To construct plasmids pTVA-Epo and pTVB-Epo
encoding TVA-Epo and TVB-Epo fusion proteins,
respectively, a 0.5 kb fragment encoding amino acids 1
to 166 of the mature erythropoietin protein [43] was
generated by PCR using plasmid R576 as a template (A
gift from Lorraine Albritton, University of Tennessee
Health Science Center, Memphis, TN) and a forward
primer (5’ CCCTCGAGGCCCCACCACGCCTCATC-3’)
and a reverse primer (5’-
GAAGGGCCCTCTGTCCCCTGTCCTGCA-3’). This
fragment was digested with XhoIa n dApaIa n ds u b -
cloned into pTVA-V5 and pTVB-V5, respectively. A
similar strategy was used to generate pTVA-SCF and
pTVB-SCF in which sequences encoding the soluble
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fused in-frame to TVA or TVB sequences. DNA
sequences encoding human SCF were generated by PCR
using pBluescriptSK-hMGF as a template and forward
primer 5’-GAGCTCGAGGAAGGGATCTGCAG-
GAATCGT-3’ and reverse primer 5’-
TTAGGGCCCGGCTGCAACAGGGGGTAACAT-3’.
Plasmid pcDNA-EpoR encoding a full length human
Epo receptor was generated by sucloning an EpoR
cDNA (pCMV6-XL4-EpoR, Origen, Rockville, MD) into
pcDNA3.1/Zeo(+). Plasmid pCMV6-XL5-c-kit-IRES-
Neo, encoding c-kit was generated by inserting IRES-
Neo sequences which were derived from plasmid
pMGIN [45] downstream of the c-kit cDNA sequence
present in pCMV6-XL5 c-kit (Origen). The pNL-EGFP/
UbC/WPREΔU3 [46], pNL-EGFP/CMV/WPREΔU3 [47],
pNL-LacZco/CMV/WPREΔU3 [48] and pCD/NL-BH*
ΔΔΔ [49] plasmids were described before.
Cell lines
Human embryonic kidney 293 (CRL-1573) and 293T
cells (CRL-11268) were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). Cells
were maintained in DMEM containing 10% heat inacti-
vated FBS, 2.5 mM L-glutamine, 100 u/ml penicillin and
100 μg/ml streptomycin (all from Invitrogen-GIBCO).
293/DK-7 cells were generated by stable transfection
with plasmid pDK7 expressing a chimeric TVA-TVB
receptor [34] (a gift from John Young). Cell clones were
maintained in medium containing 500 μg/ml of G418
(Invitrogen). 293T-EpoR cells were established by stable
transfection using the pcDNA-EpoR plasmid and cell
clones were maintained in medium containing 1 mg/ml
of Zeocin (Invitrogen). 293-c-kit cells were established
by stable transfection using the pCMV6-XL5-c-kit-IRES-
Neo plasmid and cell clones were maintained in med-
ium containing 500 μg/ml of G418. 293T cells stably
expressing TVA, TVA-Epo, TVA-SCF, TVB, TVB-Epo,
or TVB-SCF were generated by transfection with the
plasmids described above and selection using media
containing 10 μg/ml of blasticidin (Invitrogen). MO7-e
cells (obtained from Paul Schwarzenberger) were main-
tained in RPMI 1640 medium (Sigma-Aldrich, St Louis,
MO) containing 20% heat inactivated FBS (Invitrogen-
GIBCO), 2.5 mM L-glutamine, 100 u/ml penicillin, 100
μg/ml streptomycin (all from Invitrogen-GIBCO) and 10
ng/ml of GM-CSF (Sigma).
Lentiviral vector production
Lentiviral vector stocks were prepared as described
before [50]. To prepare small-scale stocks using 6-well
plates, 5 μg aliquots of the pNL-EGFP/UbC/WPREΔU3,
pNL-EGFP/CMV/WPREΔU3 or pNL-LacZco/CMV/
WPREΔU3 plasmid DNAs, plus 3.5 μgo ft h ep C D / N L -
BH* ΔΔΔ helper plasmid and 3.5 μgo ft h ep C B 6E n v A
or pAB7 Env plasmids were mixed. For vectors bearing
Sindbis virus strain TR339 glycoproteins and SCF, 5 μg
of the pNL-EGFP/UbC/WPREΔU3 vector plasmid, 3.5
μg of the pCD/NL-BH* ΔΔΔ helper plasmid, 0.25 μgo f
the SB-Env plasmid and varying amounts of the pUB-
HuMGF plasmid were used. To prepare large-scale vec-
tor stocks using 150 mm dishes, 21 μgo ft h ep N L -
EGFP/UbC/WPREΔU3 or pNL-LacZco/CMV/
WPREΔU3 plasmid DNAs plus 14 μgo ft h ep C D / N L -
BH* ΔΔΔ helper plasmid and 21 μgo ft h ep C B 6E n v A
or pAB7 Env plasmid DNAs were mixed. For concen-
trated vectors bearing the VSV-GS fusion protein and
SCF, 21 μg of the pNL-EGFP/UbC/WPREΔU3 or pNL-
LacZco/CMV/WPREΔU3 plasmid DNAs plus 14 μgo f
the pCD/NL-BH* ΔΔΔ helper plasmid, 21 μgo fp U B 6 -
VSV-GS and 21 μg of pUB6-HuMGF were mixed. For
concentrated vectors bearing the Sindbis virus strain
TR339 glycoproteins and SCF, 21 μg of the pNL-EGFP/
UbC/WPREΔU3 plasmid DNAs plus 14 μg of the pCD/
NL-BH* ΔΔΔ helper plasmid, 2.1 μgo fp c D N A - S B - E n v
and varying amount of pUB6-HuMGF were mixed. Vec-
tor stocks were concentrated by ultracentrifugation as
described before [50]. p24 antigen ELISA tests were car-
ried out as described [50].
Transduction of cells using vectors bearing fusion
domains
Transductions were performed as described before [51]
with the following modifications: 5 × 10
4 293T or 293-
c-kit cells were plated in 12 well plates. Twenty hours
later cells were transduced using lentiviral vectors bear-
ing the Sindbis virus strain TR339 glycoproteins or
VSV-GS (with or without human SCF) in the presence
of polybrene (8 μg/ml). Cells were subjected to FACS
analysis three days later. For transduction of MO7-e
cells, 2 × 10
5 cells were mixed with vector aliquots in
0.2 ml medium containing polybrene (8 μg/ml) in 12 ×
75 mm tubes, followed by spinoculation at 1,000 rpm at
25°C for 180 min and incubation at 37°C for 15 hours.
Cells were re-fed with 0.8 ml of medium and analyzed
by FACS 72 hours later.
Transduction of cells using bridge strategy
5×1 0
4 293T-EpoR cells were plated in 12-well plates.
Twenty hours later, the plates were placed on ice for 1
hour. Lentiviral vectors pseudotyped with the ALV-A or
ALV-B Env proteins were mixed with different amounts
of the bi-functional bridge proteins in the presence of
40 mM HEPES buffer (pH 7.0) and kept on ice for 30
min. Preloaded lentiviral vectors were added to pre-
chilled cells in 0.3 ml of ice-cold medium containing
polybrene (8 μg/ml). Cells were kept on ice for 30 min
before transferring them to a 37°C incubator. Alterna-
tively, 0.4 ml of ice-cold medium containing different
amounts of the bridge protein were added following
preincubation of the cells on ice for 1 hour. The cells
were kept on ice for another hour. Cells were then
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tiviral vectors pseudotyped with ALV-A (or ALV-B).
Cells were subjected to FACS analysis 72 hours post-
transduction. For transduction of MO7-e cells, 2 × 10
5
cells were chilled on ice for 1 hour and mixed with pre-
loaded vector aliquots in 0.2 ml ice-cold medium con-
taining polybrene (8 μg/ml) in 12 × 75 mm tubes. The
cells were transduced by spinoculation at 1,000 rpm at
25°C for 180 min and incubated at 37°C for 15 hours.
Cells were re-fed with 0.8 ml medium and analyzed by
FACS 72 hours later. Competition experiments were
performed by adding anti-human Epo antibody or anti-
human SCF antibody (R & D Systems Inc. Minneapolis,
MN) as indicated in the figure legends. Cells were
washed and fresh medium was added. Cells were sub-
jected to FACS analysis as described above.
Quantitation of TVA and TVB fusion proteins by ELISA
To determine the relative amounts of the bridge pro-
teins produced, an ELISA assay based on the V5 epitope
present in all TVA and TVB proteins was established.
To determine bridge protein levels, 5 × 10
6 293T cells
expressing TVA, TVA-Epo, TVA-SCF, or TVB, TVB-
Epo or TVB-SCF were seeded in T75 flasks with 15 ml
medium containing blasticidin (10 μg/ml). Cell superna-
tants were recovered three days later and centrifuged at
1500 rpm for 5 min to remove cell debris. Aliquots of
the supernatants were stored at -80°C. The relative
amounts of the bi-functional fusion proteins released by
the cells were determined using an ELISA test. This test
was performed as follows: 50 μl aliquots of serial dilu-
tions of cell supernatants or the purified V5 peptide
(Sigma) in culture medium were used to coat 96-well
plates (Nunc Maxisorp, Nalge Nunc International,
Rochester, NY) at 25°C overnight. The plates were
washed with phosphate-buffered saline (PBS) and incu-
bated with 400 μl blocking solution (PBS containing
0 . 0 5 %T w e e n2 0a n d5 %n o n f a tm i l k ,P B S T M )a t2 5 ° C
for 2 hours, followed by incubation with 50 μl of mono-
clonal anti V5 antibody (Invitrogen, 1: 2,500 dilution in
PBSTM) for 2 hours. After extensive washing with
PBST, 50 μl of goat anti-mouse IgG conjugated with
HRP (BioRad Hercules, CA, 1: 5,000 dilution in
PBSTM) was added to each well and the plates were
incubated at 25°C for 1 hour and then washed. The
plates were processed for staining using 3,3’,5,5’-tetra-
methylbenzidine (TMB, Sigma-Aldrich) as a substrate.
The concentrations of the bi-functional proteins were
determined using the purified V5 peptide (Sigma) as a
standard. The concentrations are referred to as V5
equivalent units/ml.
Analysis of TVA and TVB fusion proteins by Western
blotting
For Western blots [52] 2 to 20 μl aliquots of cell culture
supernatants were collected from transfected 293T cells.
Alternatively, lentiviral vector stocks (unconcentrated or
concentrated by ultracentrifugation) were analyzed.
Samples were treated with 50 mM Tris-HCl (pH 7.0)
buffer containing 1% SDS, 5% b-mercaptoethanol, 12.5%
glycerol and 0.01% bromophenol blue at 95°C for 5 min
and subjected to SDS-PAGE using 4-12% NuPAGE Bis-
Tris gels in MES buffer (Invitrogen) and blotted onto a
PVDF membrane (Millipore, Bedford, MA). The mem-
brane was blocked with 5% nonfat milk in TBST solu-
tion (Sigma-Aldrich), and incubated with monoclonal
anti V5 antibody (Invitrogen, 1: 2,500) followed by
HRP-conjugated goat anti-mouse IgG (BioRad 1:5,000).
Blots were treated using the SuperSignal West Pico
Chemiluminescent substrate reagent (Pierce Biotechnol-
ogy Inc., Rockford, IL) and exposed to X-ray films.
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